



Talanx

equinet Analyser

01.10.2013

Sales Desk

Aleksandar Bakrac Tel.: +49 69 58997 425

Eugenia Belova Tel. +49 69 58997 417

Jens Buchmüller Tel.: +49 69 58997 429

Achim Böckmann Tel.: +49 69 58997 424

Werner Fronk Tel.: +49 69 58997 409

Alexander Kravkov Tel.: +49 69 58997 428

Jan Neynaber Tel.: +49 69 58997 403

Marc Schellenberger Tel.: +49 69 58997 404

Guido Schickentanz Tel.: +49 69 58997 407

Marco Schumann Tel.: +49 69 58997 423

Michael Schuhmacher Tel.: +49 69 58997 400

Heinz Zörgiebel Tel.: +49 69 58997 406

Company Comments

Daldrup & Soehne

Future strategy of HDI Leben (Accumulate)

Transformation continues ... also in H1 13 (Accumulate)

Statistics							
Index	Closing	1 Day	Month	6 Months	Ytd	52w High	_
DAX	8.594	-0,8%	6,1%	10,3%	12,9%	8.770	
MDAX	15.034	-0,3%	4,5%	12,9%	26,2%	15.188	
Tec-DAX	1.084	-0,4%	6,2%	16,3%	30,8%	1.088	
SDAX	6.393	0,0%	4,3%	12,2%	21,8%	6.431	
Bund-Future	140	0,0%	-0,1%	-3,4%	-3,5%	147	
DAX Movers				MDAX Movers			
Most up	1 Day	Most down	1 Day	Most up	1 Day	Most down	
DEUTSCHE BOE	0,7%	INFINEON TEC	-2,4%	NORMA GROUP	2,6%	WINCOR NIXDO	
THY SSENKRUPP	0,5%	CONTINENTAL	-2,0%	SUEDZUCKER A	1,8%	PROSIE SAT.1	
MERCK KGAA	0,3%	E.ON SE	-2,0%	LEONI AG	1,7%	CELESIO AG	
ADIDAS AG	0,1%	HEIDELBERGCE	-2,0%	GERRY WEBER	1,7%	MTU A ERO ENG	
HENKEL AG-P	-0,1%	COMMERZBANK	-1,9%	ELRINGKLINGE	1,4%	GILDEMEISTER	
TecDax Movers				SDAX Movers			
Most up	1 Day	Most down	1 Day	Most up	1 Day	Most down	
STRATEC BIOM	2,1%	DIALOG SEMIC	-4,4%	DELTICOM AG	2,1%	AMADEUS FIRE	
CARL ZEISS M	1,9%	CANCOMAG	-4,1%	ZOOPLUS AG	1,8%	HORNBACH HLD	
EVOTEC AG	1,6%	DRA EGERWERK-	-3,8%	WACKER NEUSO	1,7%	AIR BERLIN P	
SARTORIUS AG	1,6%	ADVA OPTICAL	-2,9%	CTS EVENTIM	1,5%	PATRIZIA IMM	
PSIAG	1,5%	LPKF LASER &	-2,2%	BAYWA AG-VIN	1,4%	BAUER AG	

Publishe

equinet Bank AG 60487 Frankfurt, Gräfstr. 97 Website: www.equinet- ag.de For our disclosures in respect of section 34b of the German Securities Trading Act (Wertpapierhandelsgesetz) and our disclaimer please see the end of this document. The following internet link provides further remarks on our financial analyses: www.equinet-ag.de

Daldrup & Soehne

Germany/Renewable Energy

Analyser



Accumulate	
Recommendation unchanged	
Share price: EUR	13.15
closing price as of 30/09/2013	
Target price: EUR	15.00
Target Price unchanged	
Reuters/Bloomberg	4DSG.DE/4DS GR
Market capitalisation (EURm)	72
Current N° of shares (m)	5
Free float	34%
Daily avg. no. trad. sh. 12 mth	821

0

14.19

9.25

-1 13%


Daily avg. trad. vol. 12 mth (m)

Price high 12 mth (EUR)

Price low 12 mth (EUR)

Abs. perf. 1 mth

Abs. perf. 3 mth			9.58%
Abs. perf. 12 mth			17.94%
Key financials (EUR)	12/12	12/13e	12/14e
Sales (m)	23	51	55
EBITDA (m)	6	7	11
EBITDA margin	26.0%	14.6%	19.2%
EBIT (m)	2	4	7
EBIT margin	9.2%	7.4%	11.9%
Net Profit (adj.)(m)	2	1	3
ROCE	2.7%	4.2%	7.4%
Net debt/(cash) (m)	2	12	7
Net Debt/Equity	0.0	0.2	0.1
Debt/EBITDA	0.4	1.6	0.6
Int. cover(EBITDA/Fin. int)	(11.3)	6.8	6.0
EV/Sales	3.2	1.7	1.5
EV/EBITDA	12.3	11.7	7.8
EV/EBITDA (adj.)	12.3	11.7	7.8
EV/EBIT	34.8	23.2	12.6
P/E (adj.)	39.4	nm	21.9
P/BV	1.1	1.1	1.1
OpFCF yield	24.1%	-14.0%	6.3%
Dividend yield	0.0%	0.0%	0.0%
EPS (adj.)	0.31	0.16	0.60
BVPS	11.47	11.64	12.23
DPS	0.00	0.00	0.00



Shareholders: Daldrup Family 66%;

Analyst(s):

Michael Schaefer, Equinet Bank michael.schaefer@equinet-ag.de +49 69 58997 419

Transformation continues ... also in H1 13

The facts: Daldrup reported solid H1 13 results with EBIT gaining 10% y-y to EUR 0.88m, according to our calculation. This is based on output-growth of 66% y-y to EUR 34.2m. Start-up losses related to the at-equity participation in Geothermie Taufkirchen sends pre-tax profit and net income down to break-even level.

Daldrup & Söhne Group - Review H1 2013

EUR m	H1 13	H1 12	y-y (%)	2013e	2012e	y-y (%)
Sales	24.12	3.89	520%	51.35	22.69	126%
Total Output	34.21	20.61	66%	51.35	45.39	13%
EBITDA	2.76	2.68	3%	7.48	5.89	27%
EBIT	0.88	0.80	10%	3.80	2.09	82%
Margin (% of output)	2.6%	3.9%		7.4%	4.6%	
EBT	0.06	0.48	-88%	1.74	1.81	-4%
EAT	-0.09	0.06	-261%	1.26	1.16	8%
Minorities	0.06	0.53	-88%	-0.36	0.54	-167%
Net income attr. to shareh.	-0.03	0.59	n.m.	0.89	1.71	-48%
Adj. net income (e)	-0.03	0.59	n.m.	0.89	1.71	
Adj. EPS (EUR per share)	-0.01	0.11	n.m.	0.16	0.31	-48%

Source: Daldrup, equinet

Our analysis: Extended idle periods weigh ... Extended idle periods in deep drilling projects in the Netherlands weighed significantly on profitability in H1 13, according to Daldrup. Nevertheless, the company expects to catch-up with the original schedule (and P&L accounting) in the second half. However, we've repeatedly hinted on the pricing-in of regular cost overruns due to regulatory delays.

Taufkirchen ... at-equity accounting distorts comparability: Daldrup's stake in the geothermal energy project in Taufkirchen fell below 50% in H2 12 and is now accounted at-equity. Hence, consolidated group results in H2 12 still include the fully consolidated impact from Taufkirchen. Start-up losses at Taufkirchen are primarily reflected in EUR -0.61m results from investments below the EBIT-line.

2013e outlook confirmed ... output of EUR 52m and 6% EBIT-Margin: The company reiterated its outlook to grow output to EUR 52m in FY 13e. Targeted EBIT-Margin of 6% implies an EBIT of EUR 3.1m (e: EUR 3.8m).

Conclusion & Action: Project-based activities of Daldrup always imply a hockeystick second half earnings contribution. This is true for 2013e, too. We confirm our view on the company: Strong market and company potential, but transformation is still ongoing. Accumulate.



Talanx Group


Germany/Insurance

Analyser



Accumulate)		
Recommendation unch	nanged		
Share price: EU	R	2	24.90
closing price as of 30/09/2013			
Target price: El	JR	2	27.00
Target Price unchange	ed		
Reuters/Bloomberg		TLXG	.DE/TLX GF
Market capitalisation (EUF	Rm)		6,307
Current N° of shares (m)			253
Free float			14%
Daily avg. no. trad. sh. 12 r	nth		145,688
Daily avg. trad. vol. 12 mth	(m)		3,620
Price high 12 mth (EUR)			25.88
Price low 12 mth (EUR)			18.50
Abs. perf. 1 mth			3.32%
Abs. perf. 3 mth			2.66%
Abs. perf. 12 mth			
Key financials (EUR)	12/12	12/13e	12/146
Life Gross premiums (m)	10,664	11,342	12,050
No. 1 15 O	45.005	47.040	40.075

Vary financials (FUD)	12/12	12/13e	12/14e
Key financials (EUR)			
Life Gross premiums (m)	10,664	11,342	12,050
Non-Life Gross prem.(m)	15,995	17,012	18,075
Total Net Revenues (m)	26,599	28,400	30,136
Life Ins.Tech.Result (m)	-478	-392	-391
Non-Life Ins. Tech.Result	-955	-1,018	-945
EBIT (m)	1,760	1,915	2,073
Net Profit (adj.) (m)	630	700	762
Shareholders Equity (m)	7,472	7,838	8,296
ANAV (m)	8,120	8,948	9,406
ROE (adj.) (%)	9.8	9.1	9.4
Combined ratio (%)	96.4	97.0	97.0
P/E (adj.)	7.5	9.0	8.3
P/BV	0.6	0.8	0.8
P/ANAV	0.6	0.7	0.7
P/EbV	0.5	0.6	0.5
Dividend Yield	4.2%	4.4%	4.8%
EPS (adj.)	2.87	2.77	3.01
BVPS	34.07	30.94	32.75
ANAVPS	37.02	35.33	37.13
EbVPS	47.25	44.46	46.56
DPS	1.05	1.10	1.20



Shareholders: HDI V.a.G. 79%; Meiji Yasuda 7%;

Analyst(s):

Philipp Häßler, CFA, Equinet Bank philipp.haessler@equinet-ag.de +49 69 58997 414

Talanx looks at different options for HDI Leben

The facts: In an interview with the Süddeutsche Zeitung Talanx's CEO said that the insurer is considering different options for its life insurance business under the HDI-Lebensversicherung brand. All options (run-down, sale to a specialist) are possible. Reason for this is the low interest rate environment which makes it difficult for life insurers with old contracts (with high guarantee rates) to be profitable. We assume that most of the German life insurance companies are thinking about different options for their life insurance business which comes more and more under pressure from the low interest rates.

Our analysis:

Talanx's German retail business has generated an operating profit of EUR 98m in 2012, group operating profit stood at EUR 1,760m. HDI Leben should have generated an estimated operating profit of below EUR 35m in 2012.

The reason for the difficult situation of the German life insurers is the low interest rate environment which is particularly negative for life insurers with old contracts (with high guarantee rates). HDI Gerling achieved an average running yield of 3.8% while having an average guarantee rate of 3.3%, i.e. the spread amounted to 0.5%-pts. For other carriers within the group the spread stood at 1.8%-pts. (Targo Versicherungen) and 1.5%-pts. (PB Versicherungen), respectively.

Generally Talanx has a relatively high proportion of unit-linked business. While 60% of the market (in-force business) was traditional life and 21% unit-linked business in 2012, TLX had only 51% of traditional life and 36% of unit-linked business.

Conclusion & Action: It is no secret that the low interest rate environment makes life difficult for German life insurers. Hence, it is no big surprise in our view that Talanx is mulling different options for its life insurance business. As we do not expect yields to increase significantly in the short term, we see it positively, that Talanx is looking at all options for HDI-Lebensversicherung and is not ruling out anything.

We stick to our Accumulate rating with a TP of EUR 27.00 as the shares remain attractively valued with a 2014e PER of 8.4x.



History of equinet's Recommendations

Recommendation history for DALDRUP & SOEHNE (DE) EUR 13.15							
Date	Recommendation	Price at change date	Target Price at change date				
14. Jan 10	Accumulate	23,55	26,00				
07. Jan 09	Hold	28,00	25,00				
23. Sep 08	Accumulate	28,35	34,00				
29. Mai 08	Hold	36,00	34,00				
22. Apr 08	Rating Suspended	32,00					
07. Feb 08	Accumulate	22,75	25,00				
06. Feb 08	Not rated	22,95					

Recommendation history for TALANX GROUP (DE) EUR 24.9						
Date	Recommendation	Price at change date	Target Price at change date			
21. Mrz 13	Accumulate	23,67	26,00			
29. Nov 12	Buy	20,00	24,00			



Recommendations and Disclosures

Coverage	Analyst	Target	Rating	Disc.	Coverage	Analyst	Target	Rating	Disc.
4SC	Miemietz	3,60	Buy	7	KronesAG	Schmidt	71,00	Accumulate	
Aareal Bank	Häßler	21,00	Hold		KTGAgrar	Schäfer	16,00	Accumulate	2/3/5
Adler Modemaerkte	Rigters/Faust	10,70	Buy	3/5	KUKA	Schmidt	38,00	Accumulate	
Ad pepper	Rigters/Pehl	1,50	Buy	2/3	LANXESS	Demidova	52,00	Hold	
adidas	Faust / Rigters	85,00	Accumulate		Leoni	Schuldt	50,00	Buy	
Advanced Vision Technology	Schmidt	7,00	Buy		Linde	Demidova	160,00	Accumulate	
Aixtron	Pehl	7,00	Sell	2/3	Loewe	Faust / Rigters	Suspended	Suspended	2/5
Allianz	Häßler	120,00	Hold		Logwin	Rothenbacher	1,60	Buy	2/3/5
Analytik Jena	Demidova	14,00	Hold	7	Lufthansa	Rothenbacher	15,00	Hold	
BASF	Demidova	75,00	Hold		MAN	Schuldt	85,00	Hold	
BAUERAG	Schmidt	16,50	Reduce		MAXAutomation AG	Schmidt	7,00	Buy	2/3
Bayer	Miemietz	94,00	Accumulate		Medion	Faust / Rigters	13,00	Hold	
BayWa	Schäfer	45,00	Buy	5	Merck	Miemietz	133,00	Accumulate	
BBBiotech	Miemietz	115,00	Buy	7	MIFA	Rigters/ Faust	9,30	Buy	2/4/5
Beiersdorf	Demidova	52,00	Sell	•	MLP	Häßler	6,80	Buy	2/3
Berentzen	Faust / Rigters	6,50	Hold	2/3	Mobotix AG	Pehl	19,00	Accumulate	2/3
	-				MTU				
Beta Systems Software	Schuldt	2,60	Buy	2/3/5		Pehl	72,50	Accumulate	2
BILFINGER SE	Faust	80,00	Hold		Munich Re	Häßler	150,00	Hold	_,_,_
Biotest	Miemietz	70,00	Buy	2/3/5	Nanogate AG	Demidova	29,00	Buy	2/3/5
BMW	Schuldt	88,00	Buy		PATRIZIA AG	Häßler	9,10	Buy	
Celesio	Lieder	18,00	Accumulate		Pfeiffer Vacuum	Pehl	78,00	Reduce	
Cenit	Pehl	11,00	Buy	2/3	Phoenix Solar	Freudenreich	Suspended	Suspended	
comdirect	Häßler	6,60	Sell		Porsche	Schuldt	64,00	Hold	
Commerzbank	Häßler	10,00	Hold		Postbank	Häßler	32,00	Accumulate	
Continental	Schuldt	105,00	Reduce		PSI	Schäfer	12,00	Hold	2
Daimler AG	Schuldt	46,00	Reduce		Puma	Faust / Rigters	200,00	Reduce	
Daldrup & Soehne	Schäfer	15,00	Accumulate	2/3/5	Rheinmetall	Pehl	45,00	Hold	
Deut sche Bank	Häßler	40,00	Accumulate		Rhoen-Klinikum	Lieder	23,60	Buy	
Deut sche Biogas	Schäfer	6,00	Buy	2/3/5	RIB Software	Rothenbacher	8,00	Buy	2/3
Deut sche Boerse	Häßler	48,00	Sell	2/0/0	RWE	Schäfer	25,00	Hold	2/0
		32,00			SAF-HOLLAND		13,00		7
Deut sche EuroShop	Rothenbacher		Hold	0/0/4/5		Schuldt		Buy	,
Deut sche Forfait	Häßler	6,40	Buy	2/3/4/5	Salzgitter	Freudenreich	36,00	Buy	0/0/5
Deut sche Post	Rothenbacher	24,00	Hold		Seven Principles AG	Pehl	5,50	Buy	2/3/5
Deut sche Telekom	Pehl	10,00	Accumulate		SingulusTechnologies	Freudenreich	1,95	Buy	4/5
Deut z AG	Schmidt	6,50	Hold		SKWStahl	Freudenreich	23,00	Buy	
DouglasHolding	Faust / Rigters	38,00	Hold		SMA Solar Technology	Freudenreich	19,00	Sell	
Drägerwerk	Lieder	105,00	Accumulate		SMTSCHARFAG	Schmidt	22,00	Hold	2/3
E.ON	Schäfer	14,00	Hold		SolarWorld	Freudenreich	0,05	Sell	
ElringKlinger	Schuldt	20,00	Reduce		Solutronic	Freudenreich	Under review	Not rated	2/3
EpigenomicsAG	Miemietz	4,00	Buy	2/3/5	SuessMicroTec	Pehl	11,00	Buy	2/3
Euromicron AG	Pehl	24,00	Buy	2/3/5	SURTECO	Lieder	23,50	Buy	2/3
Fielmann	Lieder	84,00	Accumulate		Symrise AG	Demidova	26,00	Sell	
Fraport	Rothenbacher	56,00	Buy		Talanx Group	Häßler	27,00	Accumulate	
Freenet	Pehl	21,00	Accumulate	2	ThyssenKrupp	Freudenreich	18,00	Hold	
Fresenius	Lieder	104,00	Accumulate	-	TUI	Rothenbacher	12,00	Buy	
Fresenius Medical Care	Lieder	55,00	Accumulate		United Internet	Pehl	26,50	Hold	
FuchsPetrolub	Demidova	48,00	Reduce		UzinUtz	Faust / Lieder	26,00		2/3
GEA Group							2,80	Buy	2/3
	Schmidt	32,00	Buy		VBH Holding	Faust		Hold	2/3
Gerresheimer AG	Lieder	45,00	Hold		VIB Vermoegen	Rothenbacher	13,00	Buy	
GERRYWEBER	Rigters/Faust	34,00	Accumulate		Volkswagen	Schuldt	185,00	Buy	
Gesco	Schmidt	80,00	Accumulate	2/3	Vossloh	Schmidt	55,00	Sell	
GFTTechnologies	Schuldt	5,70	Buy	2/3	Wacker Chemie	Freudenreich	58,00	Sell	
Gigaset	Rigters/Pehl	1,00	Hold	2/3/5	Wilex	Miemietz	3,00	Buy	2/3
Gildemeister	Schmidt	22,00	Accumulate		Wincor Nixdorf	Pehl	49,00	Hold	2
Grenkeleasing AG	Häßler	50,00	Sell						
Hannover Re	Häßler	70,00	Buy						
Heidelberger Druck	Schmidt	2,40	Buy						
Henkel	Demidova	56,00	Sell						
HHLA	Rothenbacher	18,00	Hold						
Hochtief	Faust	69,00	Buy						
Hugo Boss	Faust / Rigters	88,00	Hold						
i:FAOAG	Rothenbacher	15,50	Buy	2/3					
			-	2/3					
IVGImmobilien AG	Rothenbacher	0,05	Sell						
K+SAG	Schäfer	47,00	Buy						
KHD HUMBOLDT WEDAG INTERNA		7,60	Buy						
Kontron	Pehl	4,50	Accumulate						

Source: equinet Recommendations





Notice according to § 34 b (German) Securities Trading Act ("Wertpapierhandelsgesetz")

This document is issued by equinet Bank AG ("equinet"). It has been prepared by its authors independently of the Company, and none of equinet, the Company or its shareholders has independently verified any of the information given in this document.

equinet possesses relations to the covered companies as detailed in the table on the previous page. Additional information and disclosures will be made available upon request and/or can be looked up on our website http://www.equinet-ag.de

- 1 equinet and/or its affiliate(s) hold(s) more than 5% of the share capital of this company calculated under computational methods required by German law.
- 2 equinet acts as a designated sponsor for this company, including the provision of bid and ask offers. Therefore, we regularly possess shares of the company in our proprietary trading books, equinet receives a commission from the company for the provision of the designated sponsor services.
- 3 The designated sponsor services include a contractually agreed provision of research services.
- 4 Within the last twelve months, equinet was involved as a lead or co-lead manager in the public offering of securities which are/whose issuer is the subject of this report.
- 5 Within the last twelve months, equinet and/or its affiliate(s) provided investment banking- and/or other consultancy services for this company and/or it's shareholders
- 6 equinet and/or its affiliate(s) has/have other substantial financial interests in relation to this issuer.
- 7 equinet has entered into an agreement with this company about the preparation of research reports and in return receives a compensation.

Companies of the equinet group and/or its directors, officers and employees or clients may take positions in, and may make purchases and/or sales as principal or agent in the securities or related financial instruments discussed in our reports. The equinet group may provide investment banking and other services to and/or serve as directors of the companies referred to in our reports.

In compliance with Para 5 Sec. 4 of the Ordinance on the Analysis of Financial Instruments (FinAnV) equinet has realized additional internal and organizational measures, such as specific research guidelines, to prevent or manage conflicts of interest.

Neither the company nor its employees are allowed to receive donations from third parties with a special interest in the content of the analysis.

The salary of the research analysts of equinet Bank AG does not depend on the investment banking transactions of the company. Nevertheless, this does not rule out the payment of a bonus which depends on the overall financial performance of the bank.

Particular care is taken that the individual performance of each research analyst of equinet Bank AG is not being assessed by a manager of another business division with similar or same interests.

To assure a highest degree of transparency equinet Bank AG regularly provides - on a quarterly basis - a summary according to Para 5 Sec. 4 No. 3 of the Ordinance on the Analysis of Financial Instruments (FinAnV). It informs about the overall analysts recommendations and sets them in a relationship to those companies, for which equinet provided investment banking services within the last twelve months. This summary is published via our website http://www.equinet-ag.de.

Furthermore, we refer to our conflict of interest policy as well as the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) provided in the download area of our website http://www.equinet-ag.de.

Remarks

Recommendation System

Buy - The stock is expected to generate a total return of over 20% during the next 12 months time horizon.

Accumulate - The stock is expected to generate a total return of 10% to 20% during the next 12 months time horizon.

Hold - The stock is expected to generate a total return of 0% to 10% during the next 12 months time horizon.

Reduce - The stock is expected to generate a total return of 0 to -10% during the next 12 months time horizon.

Sell - The stock is expected to generate a total return below -10% during the next 12 months time horizon.

Basis of Valuation

Equinet uses for valuation purposes primarily DCF-Valuations and Sum-Of-The-Parts-Valuations as well as peer group comparisons.

Share prices

Share prices in this analysis are the German closing prices of the last trading day before the publication.

Sources

equinet has made any effort to carefully research all information contained in the analysis. The information on which the analysis is based has been obtained from sources which we believe to be reliable such as, for example, Reuters, Bloomberg and the relevant press as well as the company which is the subject of the analysis. Only that part of the research note is made available to the issuer, who is the subject of the analysis, which is necessary to properly reconcile with the facts. Should this result in considerable changes a reference is made in the research note.

Actualizations

Opinions expressed in this analysis are our current opinions as of the issuing date indicated on this document. We do not commit ourselves in advance to whether and in which intervals updates are made.



DISCLAIMER

THE PREPARATION OF THIS DOCUMENT IS SUBJECT TO REGULATION BY GERMAN LAW. THIS DOCUMENT IS BEING SUPPLIED TO YOU SOLELY IN YOUR CAPACITY AS A PROFESSIONAL INSTITUTIONAL INVESTOR FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. NEITHER THIS DOCUMENT NOR ANY COPY OF IT MAY BE TAKEN OR TRANSMITTED INTO AUSTRALIA, CANADA OR JAPAN OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN OR TO ANY RESIDENT THEREOF.

THE DELIVERY OF THIS RESEARCH REPORT TO U.S. PERSONS IN THE UNITED STATES OF AMERICA IS MADE BY AND UNDER THE RESPONSIBILITY OF ESN NA, INC. (REGISTERED WITH THE SEC). THIS RESEARCH REPORT IS ONLY INTENDED FOR PERSONS WHO QUALIFY AS MAJOR U.S. INSTITUTIONAL INVESTORS, AS DEFINED IN SECURITIES EXCHANGE ACT RULE 15A-6, AND DEAL WITH ESN NA, INC. HOWEVER, THE DELIVERY OF THIS RESEARCH REPORT OR SUMMARY TO ANY U.S. PERSON SHALL NOT BE DEEMED A RECOMMENDATION OF ESN NA, INC. TO EFFECT ANY TRANSACTIONS IN THE SECURITIES DISCUSSED HEREIN OR AN ENDORSEMENT OF ANYOPINION EXPRESSED HEREIN. ESN NA, INC. MAY FURNISH UPON REQUEST ALL INVESTMENT INFORMATION AVAILABLE TO IT SUPPORTING ANY RECOMMENDATIONS MADE IN THIS RESEARCH REPORT. ALL TRADES WITH U.S. RECIPIENTS OF THIS RESEARCH SHALL BE EXECUTED THROUGH ESN NA, INC.

THIS DOCUMENT IS FOR DISTRIBUTION IN THE U.K. ONLY TO PERSONS WHO HAVE PROFESSSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") OR (ii) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, NAMELY HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED UPON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS DOCUMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THE DISTRIBUTION OF THIS DOCUMENT IN OTHER JURISDICTIONS OR TO RESIDENTS OF OTHER JURISDICTIONS MAY ALSO BE RESTRICTED BY LAW, AND PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY SUCH RESTRICTIONS. BY ACCEPTING THIS REPORT YOU AGREE TO BE BOUND BY THE FOREGOING INSTRUCTIONS. YOU SHALL INDEMNIFY EQUINET BANK AGAINST ANY DAMAGES, CLAIMS, LOSSES, AND DETRIMENTS RESULTING FROM OR IN CONNECTION WITH THE UNAUTHORIZED USE OF THIS DOCUMENT.

This report is for informational purposes only and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: readers must exercise their own inde-pendent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.

The information herein is believed by equinet to be reliable and has been obtained from sources believed to be reliable, but equinet makes no representation as to the accuracy or completeness of such information. The information given in this report is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the Company. Opinions expressed herein may differ or be contrary to opinions expressed by other business areas of the equinet group as a result of using different assumptions and criteria, equinet is under no obligation to update or keep the information current, equinet provides data concerning the future development of securities in the context of its usual research activity. However, if a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments de-scribed in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results. Neither the author nor equinet accepts any liability whatsoever for any loss howsoever arising from any use of this publication or its contents or otherwise arising in connection herewith, except as provided for under applicable regulations.

equinet shall only be liable for any damages intentionally caused or which result from any gross negligence of equinet. Further equinet shall be liable for the breach of a material obligation of equinet, however, limited to the amount of the typical foreseeable which shall in no event exceed the amount of EUR 10,000. German law shall be applicable and court of jurisdiction for all disputes shall be Frankfurt/Main (Germany).

Competent Supervisory Authority:

Bundesanstalt für Finanzdienstleistungsaufsicht -BaFin- (Federal Financial Supervisory Authority) Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Str. 24-28, 60439 Frankfurt am Main.